TCGA-A2-A0ES-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.480
- UV_RESPONSE_DN+0.480
- ESTROGEN_RESPONSE_EARLY+0.400
- TGF_BETA_SIGNALING+0.380
- ANDROGEN_RESPONSE+0.370
- KRAS_SIGNALING_UP+0.360
- WNT_BETA_CATENIN_SIGNALING+0.350
- ANGIOGENESIS+0.340
- APICAL_JUNCTION+0.340
- IL6_JAK_STAT3_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- E2F_TARGETS-0.620
- MYC_TARGETS_V1-0.530
- G2M_CHECKPOINT-0.520
- OXIDATIVE_PHOSPHORYLATION-0.510
- DNA_REPAIR-0.460
- MTORC1_SIGNALING-0.350
- GLYCOLYSIS-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.240
- PEROXISOME-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.944 |
| 2 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.927 |
| 3 | TCGA-CR-7393-01A-11R-2016-07 | — | — | 0.925 |
| 4 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.918 |
| 5 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.917 |
| 6 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.917 |
| 7 | ULC1729T_S65 | — | cohortSQ1 | 0.916 |
| 8 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.911 |
| 9 | SRR4296080 | — | cohortA1 | 0.904 |
| 10 | SRR35579845 | — | A | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.480 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |